Sobi to Acquire Arthrosi Therapeutics for Gout Pipeline

Sobi announced it has acquired Arthrosi Therapeutics to strengthen its pipeline for novel gout therapies. The deal is positioned as an add-on to Sobi’s broader development efforts in gout treatment.

The transaction is described as supporting future development of gout-focused programs, aligning Arthrosi’s therapeutic work with Sobi’s substance-abuse-treatment and healthcare R&D priorities as presented in the deal materials.